Phase 2 Study of Irinotecan Liposome or Etoposide Combined With Adebrelimab and Carboplatin for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the safety and effectiveness of two drug combinations as first-line treatments for extensive stage small cell lung cancer ES-SCLC. This phase II, randomized, parallel, multicenter study compares irinotecan liposome II combined with adebrelimab and carboplatin versus etoposide combined with adebrelimab and carboplatin. The main goal is to measure the 1-year overall survival rate in patients with this condition. Participants receive one of two treatments one group gets irinotecan liposome II with adebrelimab and carboplatin, while the other receives etoposide with adebrelimab and carboplatin. Treatments are given as part of the initial therapy for ES-SCLC. The study tracks patients through these treatments to compare how the combinations work and their safety profiles. During the study, participants undergo regular assessments including survival monitoring, progression-free survival, response rates, disease control, duration of response, and adverse events over periods ranging from one to three years. These evaluations help researchers understand the treatments impact and safety. The study is sponsored by the Guangzhou Institute of Respiratory Disease and includes adult patients aged 18 to 70 years with confirmed ES-SCLC who meet specific health and organ function criteria.

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC